Aristotle Capital Management LLC Sells 94,654 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Aristotle Capital Management LLC lowered its position in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,296,080 shares of the company's stock after selling 94,654 shares during the quarter. Aristotle Capital Management LLC's holdings in Roche were worth $80,332,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of RHHBY. Brooklyn Investment Group boosted its holdings in shares of Roche by 36.6% during the 4th quarter. Brooklyn Investment Group now owns 1,354 shares of the company's stock valued at $48,000 after purchasing an additional 363 shares during the last quarter. Verity Asset Management Inc. boosted its stake in Roche by 26.8% during the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company's stock valued at $280,000 after buying an additional 1,697 shares during the last quarter. HighPoint Advisor Group LLC grew its holdings in Roche by 2.8% during the 4th quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock valued at $387,000 after buying an additional 304 shares in the last quarter. Confluence Investment Management LLC increased its stake in Roche by 26.3% in the 4th quarter. Confluence Investment Management LLC now owns 13,981 shares of the company's stock worth $488,000 after acquiring an additional 2,910 shares during the last quarter. Finally, SVB Wealth LLC purchased a new stake in shares of Roche during the 4th quarter worth approximately $555,000.

Roche Price Performance

RHHBY traded down $0.63 during trading hours on Tuesday, reaching $40.70. 3,043,197 shares of the company's stock traded hands, compared to its average volume of 3,048,702. The firm has a 50-day moving average price of $40.66 and a 200 day moving average price of $38.64. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97. Roche Holding AG has a 52-week low of $30.06 and a 52-week high of $44.31.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RHHBY. UBS Group raised shares of Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. HSBC lowered Roche from a "buy" rating to a "hold" rating in a research report on Monday, April 28th. Sanford C. Bernstein upgraded Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Hsbc Global Res cut Roche from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Finally, Morgan Stanley started coverage on Roche in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Roche has a consensus rating of "Hold".

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.